KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) EBIAT (2016 - 2025)

Historic EBIAT for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $2.2 billion.

  • Bristol Myers Squibb's EBIAT rose 8115.23% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year increase of 18342.07%. This contributed to the annual value of -$8.9 billion for FY2024, which is 21129.35% down from last year.
  • Latest data reveals that Bristol Myers Squibb reported EBIAT of $2.2 billion as of Q3 2025, which was up 8115.23% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Bristol Myers Squibb's EBIAT peaked at $2.5 billion during Q1 2025, and registered a low of -$11.9 billion during Q1 2024.
  • Over the past 5 years, Bristol Myers Squibb's median EBIAT value was $1.7 billion (recorded in 2024), while the average stood at $970.3 million.
  • In the last 5 years, Bristol Myers Squibb's EBIAT skyrocketed by 134823.53% in 2021 and then crashed by 62540.8% in 2024.
  • Over the past 5 years, Bristol Myers Squibb's EBIAT (Quarter) stood at $2.4 billion in 2021, then decreased by 14.63% to $2.0 billion in 2022, then dropped by 12.99% to $1.8 billion in 2023, then plummeted by 95.91% to $72.0 million in 2024, then skyrocketed by 2956.94% to $2.2 billion in 2025.
  • Its EBIAT stands at $2.2 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $2.5 billion for Q1 2025.